[go: up one dir, main page]

AR053680A1 - Composicion - Google Patents

Composicion

Info

Publication number
AR053680A1
AR053680A1 ARP060100551A ARP060100551A AR053680A1 AR 053680 A1 AR053680 A1 AR 053680A1 AR P060100551 A ARP060100551 A AR P060100551A AR P060100551 A ARP060100551 A AR P060100551A AR 053680 A1 AR053680 A1 AR 053680A1
Authority
AR
Argentina
Prior art keywords
rotavirus
provides
phosphate
formulations
composition
Prior art date
Application number
ARP060100551A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR053680A1 publication Critical patent/AR053680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona formulaciones líquidas de rotavirus que son adecuadas para administracion oral a lactantes humanos. En particular, la presente proporciona composiciones farmacéuticas y vacunas, que comprenden un antígeno de rotavirus, un azucar y un carboxilato, en las que dicha formulacion posee un pH de entre un pH de 5.0 y un pH de 8.0 y no comprende fosfato o el fosfato es menor que 5mM. La presente también proporciona procedimientos para preparar dichas formulaciones de rotavirus y el uso de las mismas en la prevencion o tratamiento de enfermedades asociadas con rotavirus en seres humanos.
ARP060100551A 2005-02-17 2006-02-15 Composicion AR053680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions

Publications (1)

Publication Number Publication Date
AR053680A1 true AR053680A1 (es) 2007-05-16

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100551A AR053680A1 (es) 2005-02-17 2006-02-15 Composicion

Country Status (32)

Country Link
US (2) US8192747B2 (es)
EP (2) EP1863526B1 (es)
JP (1) JP5118977B2 (es)
KR (1) KR101319846B1 (es)
CN (2) CN101300028B (es)
AP (1) AP2692A (es)
AR (1) AR053680A1 (es)
AT (1) ATE516044T1 (es)
AU (1) AU2006215761B2 (es)
BR (1) BRPI0608877B8 (es)
CA (1) CA2598290C (es)
CY (1) CY1111916T1 (es)
DK (1) DK1863526T3 (es)
EA (1) EA012046B1 (es)
ES (1) ES2369246T3 (es)
GB (1) GB0503337D0 (es)
HR (1) HRP20110668T1 (es)
IL (1) IL184802A0 (es)
MA (1) MA29321B1 (es)
MX (1) MX2007010075A (es)
MY (1) MY145790A (es)
NO (1) NO341789B1 (es)
NZ (1) NZ560314A (es)
PE (1) PE20061094A1 (es)
PL (1) PL1863526T3 (es)
PT (1) PT1863526E (es)
SI (1) SI1863526T1 (es)
TW (1) TWI358303B (es)
UA (1) UA91044C2 (es)
UY (1) UY29377A1 (es)
WO (1) WO2006087205A1 (es)
ZA (1) ZA200706668B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711608B8 (pt) * 2006-05-12 2021-05-25 Bharat Biotech Int Ltd composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
WO2009042202A2 (en) * 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CA3121471A1 (en) * 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
WO2012040707A2 (en) 2010-09-24 2012-03-29 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
KR20150000389A (ko) * 2011-04-28 2015-01-02 인터내셔널 메디카 파운데이션 액상 백신 제제
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
ES2862392T3 (es) * 2012-02-08 2021-10-07 Univ Florida Composiciones y métodos para tratar diarrea
US9827303B2 (en) 2012-03-05 2017-11-28 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Methods and compositions for stabilizing dried biological materials
EP2945650B1 (en) 2012-04-23 2023-07-05 Bharat Biotech International Limited Rotavirus vaccine compositions and process for preparing the same
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
CN105120856B (zh) 2013-03-11 2019-07-09 佛罗里达大学研究基金会有限公司 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
MX2016000405A (es) * 2013-07-19 2016-09-09 Hexal Ag Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US20160206728A1 (en) * 2013-10-03 2016-07-21 Nitto Denko Corporation Dried influenza vaccine preparation and method of producing the same
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN113730564A (zh) * 2014-12-08 2021-12-03 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
CA3006069A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Thermally stable rotavirus vaccine formulations and methods of use thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2121841T3 (es) * 1990-11-16 1998-12-16 Childrens Hosp Medical Center Una vacuna para proporcionar proteccion inmunologica contra enfermedades de rotavirus en humanos.
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
EP0535723A1 (en) * 1991-08-05 1993-04-07 Sterling Winthrop Inc. Buffered formulation of capitals
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
HU219810B (hu) 1993-11-17 2001-08-28 Deutsche Om Arzneimittel Gmbh. Glükózamin-diszacharidok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, valamint alkalmazásuk
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
ATE377428T1 (de) 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
KR100766016B1 (ko) 1998-06-30 2007-10-11 옴 파르마 아실 유사디펩티드, 이의 제조 방법 및 이를 함유하는 약제 조성물
PE20010487A1 (es) 1999-08-17 2001-06-23 Smithkline Beecham Biolog Vacuna de rotavirus
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
DE60141681D1 (de) * 2000-01-28 2010-05-12 Us Gov Health & Human Serv Immunogenischen zusammensetzung von lebendigen rotaviren mit verringertem risiko von nebenwirkungen

Also Published As

Publication number Publication date
BRPI0608877A2 (pt) 2012-07-31
EA012046B1 (ru) 2009-08-28
MY145790A (en) 2012-04-30
JP5118977B2 (ja) 2013-01-16
EP1863526B1 (en) 2011-07-13
PL1863526T3 (pl) 2011-12-30
HRP20110668T1 (hr) 2011-10-31
CN103357005A (zh) 2013-10-23
US8192747B2 (en) 2012-06-05
ATE516044T1 (de) 2011-07-15
EP2322211A1 (en) 2011-05-18
AP2007004087A0 (en) 2007-08-31
BRPI0608877B8 (pt) 2021-05-25
JP2008530165A (ja) 2008-08-07
TWI358303B (en) 2012-02-21
TW200640486A (en) 2006-12-01
PE20061094A1 (es) 2006-11-30
AP2692A (en) 2013-07-16
NO20073868L (no) 2007-11-15
EP1863526A1 (en) 2007-12-12
ZA200706668B (en) 2009-07-29
NO341789B1 (no) 2018-01-22
UA91044C2 (uk) 2010-06-25
WO2006087205A1 (en) 2006-08-24
KR101319846B1 (ko) 2013-10-22
EA200701519A1 (ru) 2008-02-28
CN101300028B (zh) 2014-06-04
US20120237547A1 (en) 2012-09-20
CA2598290A1 (en) 2006-08-24
AU2006215761B2 (en) 2011-03-17
KR20070103506A (ko) 2007-10-23
MA29321B1 (fr) 2008-03-03
ES2369246T3 (es) 2011-11-28
SI1863526T1 (sl) 2011-11-30
US8821891B2 (en) 2014-09-02
CA2598290C (en) 2015-08-11
BRPI0608877B1 (pt) 2021-02-09
IL184802A0 (en) 2007-12-03
PT1863526E (pt) 2011-10-11
AU2006215761A1 (en) 2006-08-24
US20080166372A1 (en) 2008-07-10
MX2007010075A (es) 2008-01-16
CY1111916T1 (el) 2015-11-04
UY29377A1 (es) 2006-10-02
NZ560314A (en) 2011-02-25
CN101300028A (zh) 2008-11-05
GB0503337D0 (en) 2005-03-23
DK1863526T3 (da) 2011-10-24

Similar Documents

Publication Publication Date Title
AR053680A1 (es) Composicion
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
TW200806289A (en) Sustained-release formulation of zonisamide
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
DE602005008122D1 (de) Synergistische antibakterielle Formulierung und Herstellungsmethode
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BRPI0712478B8 (pt) uso de material de planta ou extrato do material de planta
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
MY159348A (en) A novel stable formulation for treatment of respiratory disorder
RU2532399C2 (ru) Способ лечения пародонтита
WO2012079721A8 (en) Terpenoid spiro ketal compounds with lxr agonists activity, their use and formulations with them
DE602006009511D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen
NZ547521A (en) Protein NMB0928 and use thereof in pharmaceutical formulations
Pal et al. KGMC incision: new approach for exposure of body of mandible
ITMI20041871A1 (it) Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce

Legal Events

Date Code Title Description
FC Refusal